A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors|Locally Advanced or Metastatic Breast or Colorectal Cancer
Interventions: DRUG: tivozanib (AV-951) and capecitabine (Xeloda®)
Sponsor: AVEO Pharmaceuticals, Inc.